Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Prostaglandins E2 and I2 bind to EP receptors on gastric cells, triggering protective mechanisms. EP3 receptors decrease gastric acid secretion through inhibitory G proteins. EP1/2 and EP4 receptors stimulate bicarbonate and mucus secretion, while EP2/4 promotes mucosal blood flow. These coordinated actions create protective barriers against mucosal injury.

NSAIDs inhibit cyclooxygenase, the enzyme responsible for synthesizing prostaglandins. This blockade reduces prostaglandin E2 and I2 production, eliminating the protective mechanisms that normally safeguard the gastric mucosa. Without adequate prostaglandin signaling, gastric acid increases unchecked, leading to mucosal damage and ulcer formation.

Misoprostol is a synthetic prostaglandin E1 analog that mimics natural prostaglandin effects. It lowers gastric acid secretion, enhances mucus and bicarbonate production, and increases mucosal blood flow. These actions counteract NSAID-induced mucosal injury and prevent ulcer formation in high-risk patients taking chronic NSAIDs.

Misoprostol commonly causes diarrhea and abdominal cramps due to its effects on gastrointestinal motility. More critically, it stimulates uterine contractions, making it contraindicated in pregnant women. Additionally, misoprostol can exacerbate inflammatory bowel disease, limiting its use in patients with this condition.

Misoprostol is rapidly absorbed from the gastrointestinal tract following oral administration. It is quickly metabolized into its active metabolite, which exerts the therapeutic prostaglandin-like effects. This rapid absorption and metabolism allow misoprostol to provide prompt mucosal protection against NSAID-induced injury.

EP3 receptors coupled to inhibitory G proteins mediate gastric acid reduction. In contrast, EP1/2 and EP4 receptors stimulate bicarbonate and mucus secretion independently. This receptor specificity allows prostaglandins to simultaneously suppress acid production while enhancing mucosal protective secretions through distinct signaling pathways.

Misoprostol works as a mucosal protective agent by enhancing bicarbonate, mucus, and blood flow rather than directly suppressing acid. Unlike acid suppressive drugs for peptic ulcer disease histamine h2 receptor antagonists or proton pump inhibitors that reduce acid production, misoprostol strengthens the mucosa's intrinsic defense mechanisms against acid damage.